News & Events: Press Releases

ARCION RECEIVES NOTICE OF ALLOWANCE FOR US PATENT FOR NOVEL TOPICAL LIDOCAINE FORMULATION FOR PAIN

01/04/12

ARCION THERAPEUTICS TO PRESENT ARC-4558 PHASE 2B DATA FOR THE TREATMENT OF PAIN ASSOCIATED WITH PAINFUL DIABETIC NEUROPATHY AT UPCOMING MEDICAL MEETING

06/14/2011

ARCION THERAPEUTICS RECEIVES FDA FAST TRACK DESIGNATION FOR ARC‐4558 FOR THE TREATMENT OF PAIN ASSOCIATED WITH PAINFUL DIABETIC NEUROPATHY

09/14/2010

ARCION'S IMPROVED (NOCI)RECEPTION

02/08/10 - BioCentury Feature Article

ARCION THERAPEUTICS' TOPICAL GEL CANDIDATE ARC-4558 DEMONSTRATES SIGNIFICANT PAIN REDUCTION IN PHASE 2b TRIAL FOR PAINFUL DIABETIC NEUROPATHY

07/20/2009

Download PDF

ARCION THERAPEUTICS' TOPICAL PAIN CANDIDATE, ARC-4558, SIGNIFICANTLY REDUCES PAIN CAUSED BY DIABETIC NEUROPATHY

05/07/2009 - Clinical Data Presented at American Pain Society Annual Meeting.

NEWS ANALYSIS - WHO'LL STOP THE PAIN?

01/07/08 - Arcion CEO Dr James Campbell Featured in Venture Capital Journal

ARCION THERAPEUTICS RAISES $8.8 MILLION "A" ROUND

01/09/2007 - Start-up's Breakthrough Work with Topical Clonidine Gel Has Potential to Improve Treatment for Neuropathic Pain.

Download PDF

©2008 Arcion Therapeutics, Inc. All Rights Reserved. | Terms of Use | 2400 Boston Street, Suite 330 | Baltimore, Maryland 21224 | P 410.522.8701 | info@arciontherapeutics.com | Design: R2i